Alkem Laboratories share news, announcements and annual reports
NSE: ALKEMBSE: 539523Pharmaceuticals & BiotechnologyMid Cap
Alkem Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2015
Last close ₹5,079.00up ₹9.00 (0.18%)BSE ₹5,050.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹5,070.00.
29 Oct: open ₹5,093.00, high ₹5,104.00, low ₹5,045.00
52-week range of traded prices to 29 Oct 2026
₹4,811.00Low, 22 Oct 2026₹5,933.50High, 13 Jan 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹60,727 Cr164th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 28.15
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.04%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 16.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.11
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 58,53051.1% delivered
Alkem Laboratories share news and announcements
793 announcements, routine notices left out, newest first. Page 3 of 16.
Dec 2025
2 Dec · General Updates
Nov 2025
25 Nov · Analysts
18 Nov · Legal
14 Nov · Analysts
13 Nov · Board meeting
13 Nov · Results
3 Nov · Legal
Oct 2025
28 Oct · Analysts
28 Oct · Analysts
1 Oct · Legal
Sep 2025
26 Sep
24 Sep · Legal
22 Sep · Legal
18 Sep · Analysts
17 Sep · Analysts
16 Sep · Analysts
8 Sep · Analysts
3 Sep · Analysts
Aug 2025
22 Aug · Analysts
12 Aug · General Updates
12 Aug · Board meeting
12 Aug · Results
11 Aug · Analysts
7 Aug · Analysts
5 Aug · Analysts
4 Aug · Board meeting
Jul 2025
25 Jul · Legal
21 Jul · Meeting
8 Jul · Management
3 Jul · Meeting
Jun 2025
26 Jun · Legal
Exchange has sought clarification from Alkem Laboratories Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.18 Jun · Management
13 Jun · Legal
13 Jun · Disclosure
12 Jun · Meeting